U.S. Patent and Trademark Office
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21 associated disorders, including metabolic conditions.
Boettcher, Brian R.; Caplan, Shari L.; Daniels, Douglas S.; Hamamatsu, Norio; Licht, Stuart; and Weldon, Stephen Craig, "Patent: Fusion Proteins for Treating Metabolic Disorders" (2013). Chemistry Faculty Publications. 102.
Pub. No.: US 2013/007.9500 A1